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Abstract (Max 250 words) 
Background 
The World Health Organization declared the novel coronavirus outbreak (COVID-19) to be a pandemic 
on March 11, 2020. Large-scale monitoring for capturing the current epidemiological situation of 
COVID-19 in Japan would improve preparation for and prevention of a massive outbreak. 
 
Methods 
A chatbot-based healthcare system named COOPERA (COvid-19: Operation for Personalized 
Empowerment to Render smart prevention And care seeking) was developed using the LINE app to 
evaluate the current Japanese epidemiological situation. LINE users could participate in the system 
either though a QR code page in the prefecture’s website, or a banner at the top of the LINE app 
screen. COOPERA asked participants questions regarding personal information, preventive actions, 
and non-specific symptoms related to COVID-19 and their duration. We calculated daily cross 
correlation functions between the reported number of infected cases confirmed by PCR and the 
symptom-positive group captured by COOPERA.  
 
Results 
We analyzed 206,218 participants from three prefectures reported between March 5 and 30, 2020. 
The mean (standard deviation) age of participants was 44.2 (13.2). No symptoms were reported by 
96.93% of participants, but there was a significantly positive correlation between the reported 
number of COVID-19 cases and self-reported fevers, suggesting that massive monitoring of fever 
might help to estimate the scale of the COVID-19 epidemic in real time.  
 
Conclusions 
COOPERA is the first real-time system being used to monitor trends in COVID-19 in Japan, and provides 
useful insights to assist political decisions to tackle the epidemic.  
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Background 
The 2019 coronavirus disease (COVID-19) outbreak was first reported in Wuhan City, Hubei Province, 
China in late December 2019 [1, 2]. Since then, the causative virus, severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has spread rapidly throughout China and to 184 countries and territories; 
as of April 7, 2020, a total of 1,430,141 confirmed cases and 82,119 deaths have been reported 
worldwide [3, 4]. 
  
In Japan there were 2,586 PCR-confirmed cases with symptoms and 80 deaths as of April 7, which is 
relatively low compared with other countries [5]. Clearer understanding of the current 
epidemiological situation of COVID-19 in Japan would improve preparation for and prevention of a 
massive outbreak, but the situation remains unclear due to the limited number of PCR tests conducted 
[6, 7]. In particular, untraceable cases have been increasing in larger cities such as Tokyo [5], which 
suggests a shift from sporadic traceable transmission to an exponentially growing major outbreak. 
Unfortunately, surveillance using PCR tests or serological surveillance is not feasible because of limited 
resources [8], and because testing of mild cases often requires them to use public transport to clinics, 
endangering the health of others. Such surveillance would also take a long time and is not capable of 
responding to outbreaks in a timely manner. Therefore, rapid and large-scale monitoring for capturing 
the current epidemiological situation of COVID-19 in Japan is needed [9]. 
  
On March 5, 2020, in Japan, Kanagawa prefectural government entered a collaboration with LINE 
Corporation [10], the provider of one of Japan’s largest mobile messenger applications with a claim to 
83 million monthly active users, accounting for 65% of Japan's total population. They launched a 
health care support system to support monitoring and follow-up of high-risk groups and potential 
cases of COVID-19, as well as to provide efficient support for those with mild symptoms [11]. This 
system was named COvid-19: Operation for Personalized Empowerment to Render smart prevention 
And care seeking [COOPERA]. COOPERA is also intended to support the prefectural government to 
rapidly grasp the epidemiological situation in the region by analyzing the data provided by the users. 
Kanagawa Prefecture plans to collaborate with other prefectures to develop COOPERA in a wide range 
of areas in Japan. The timing of the openings varied by prefecture, with the next COOPERA launch 
occurring on March 17 in Aichi Prefecture and March 18 in Shiga Prefecture. 
 
In this paper, we describe the novel health care support system, COOPERA, and the results of analyses 
of data collected in Kanagawa, Aichi, and Shiga prefectures by March 30, 2020. To validate whether 
the system captures the COVID-19 situation, we compared the data collected by COOPERA with the 
confirmed cases of COVID-19 reported in each prefecture.  
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Methods 
COOPERA 
COOPERA uses a chatbot asking the participants to provide basic information such as their current 
physical condition (non-specific symptoms, such as fatigue and fever) and their residence. Based on 
the information provided by the user, COOPERA has three major objectives: 
  
(1) Providing individualized support for self-care and suggesting preventive behavior to avoid infection 
events. 
COOPERA supports better health behavior of the participants through chatbots based on the input 
data. The system returns individualized information related to self-care or consultation with health 
care providers, and further suggests preventive actions to avoid infections (e.g. washing hands). 
  
(2) Real-time follow-up and feedback to participants 
COOPERA follows up the participants asking their health condition every other day. Depending on the 
user's answers about their physical condition, age, and medical conditions, COOPERA will provide the 
user with information that will help them take appropriate action. For example, a fever that lasts more 
than four days, or a strong feeling of weariness (fatigue) or shortness of breath, is one of the 
guideposts for contacting the Coronavirus Consultation Center as defined by the Ministry of Health, 
Labour and Welfare. In accordance with this guideline, COOPERA also provides respondents with 
information on the need to contact the Coronavirus Consultation Center, as well as contact 
information for the center depending on where the respondent lives. 
  
(3) Capturing the epidemiological situation to assist public health action 
Information collected and analyzed is shared with the public health sector, which helps  
them implement effective measures at local to national level. 
 
Participants 
COOPERA laun hed its service in Kanagawa Prefecture on March 5, followed by Aichi Prefecture on 
March 17 and Shiga Prefecture on March 18. LINE users could participate in the system either though 
the QR code page in the prefecture’s website, or the banner at the top of the LINE app screen leading 
the users to the QR code page. The banner was displayed on the app users’ phones three times in 
Kanagawa (from 6:30 p.m. to 11:59 p.m. on March 5, 3:30 p.m. to 11:59 p.m. on March 6, and from 
7:00 a.m. on March 12 to 6:59 a.m. on March 13), twice in Aichi (from 11:00am on March 19 until 
10:59am on March 20), and twice in Shiga (from 11:00am on March 19 until 10:59am on March 20). 
Due to the company policy of LINE Corporation, the users (and the COOPERA participants) are 13 years 
old or older. For those who had multiple answers within one day, only the first answer was extracted. 
 
Prefectural information 
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Maps of the three prefectures are shown in Supplementary Figure 1. Populations of Kanagawa, Aichi, 
and Shiga are 9.2 million, 7.5 million and 1.4 million, respectively, as of March 2020. In addition to the 
data collected through COOPERA, we extracted the number of COVID-19 cases (confirmed by PCR test) 
reported by each prefecture [12-14]. As of March 30, 2020, the three prefectures had identified 130, 
169, and 6 COVID-19 cases, respectively. As an overview of the health care resources of each 
prefecture, as of 2018, the number of hospitals per 100,000 population was 3.7, 4.3 and 4.0, 
respectively. The number of doctors per 100,000 population was 50.7/158.7, 45.8/161.9 and 
42.9/178.0 for women/men, respectively. 
 
Questionnaire 
COOPERA asks age, gender, occupation, medical history (malignant tumor with anticancer drugs, 
malignant tumor without anticancer drugs, cardiovascular diseases, kidney diseases, diabetes mellitus, 
receiving dialysis treatment, chronic obstructive pulmonary disease, treatment with 
immunosuppressants, and pregnant), preventive behaviors, residence information (zip code), and 
onset date of current and past month's symptoms which are surrogate indicators of COVID-19 
infection but are non-specific (presence or absence of fever, strong feeling of weariness (fatigue) or 
shortness of breath) and duration of these symptoms. For those who report symptoms, COOPERA asks 
additional questions about medical visits and clinical diagnoses at that time. In the follow-up questions, 
COOPERA asks their health condition again. In this study, four categories of symptoms are asked: fever 
above 37.5°C (Condition a), strong feeling of weariness or shortness of breath (Condition b), both 
Condition a and b (Condition c), or either Condition a or b (Condition d). In this study, we analyze and 
report the initial response to the questionnaire, and follow-up data were not accounted for. In other 
words, cases that developed symptoms after the initial response were not included in this analysis. 
  
Percentage of people with symptoms 
In this study, unless otherwise noted, the percentage of condition a–d uses both current and past-
month symptom responses; if on March 20, a person responds "fever above 37.5°C" for current 
symptoms, that person's response is reflected in both the denominator and numerator of the March 
20 percentage. Also, for the past month, if the person had a "fever above 37.5°C" on March 15, his or 
her answer will be reflected in the denominator for the past month, as well as in the numerator for 
the percentage on March 15. 
 
Statistical analysis 
Baseline data were reported as mean (SD) or proportion. For change point detection in the proportion 
of daily reported cases (for each Condition), a piecewise linear regression model was fitted with (at 
most) ten change points [15]. The difference in slopes before and after the estimated change point(s) 
was tested using the Davies test [16, 17]. 
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The relationship between two time-series data, T1) the number of cases confirmed with PCR test 
reported each day and T2) the proportion of the participants with any symptom onset, was examined 
in Kanagawa Prefecture using the sample cross correlation function (CCF) to validate that the system 
is capturing the epidemiological situation [16]. Given the delay between symptom onset to 
confirmation observed elsewhere [2], we expected that T1 and T2 should be correlated with some 
time lag. We shifted T1 by n days (-10<n<10) and calculated the correlation with T2. As a sensitivity 
check, CCF between T2 and the weekly number of influenza cases in Kanagawa Prefecture during the 
study period was calculated with lag of -5 to 5 days [18]. Statistical analyses were conducted with R 
(version 3.6.0) software. The type I error rate was fixed at 0.05. 
  
Ethics statement 
Ethical approval was granted by the ethics committee of Keio University School of Medicine, under 
authorization number 20190338. We only obtained data from those who have given consent for the 
prefecture that administers the questionnaire to provide their response data to a third party for 
research use. Respondents must give their consent on the LINE chatbot before they proceed to the 
questionnaire response page.  
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Results 
A total of 206,218 participants, including 124,766 (60.5%), 66,558 (32.3%) and 14,894 (7.2%) in 
Kanagawa, Aichi, and Shiga prefectures, respectively, were reported from March 5 to 30, 2020. Table 
1 shows the basic characteristics of the participants at the initial response date for the three 
prefectures-combined (see Supplementary Table 1 for the prefecture specific data). Most participants 
(96.93%) did not have any symptoms when enrolled in the system (i.e., No-symptom group). The 
distribution of symptomatic conditions was 1.37%, 2.38%, 0.68%, and 3.07% for Condition a, b, c, and 
d, respectively. Mean and standard deviation (SD) of age at the baseline was 44.2 (SD: 13.2). The age 
distribution of the group without symptoms was right skewed with mean (SD) age of 44.36 (13.18), 
while mean (SD) age of the group with any symptoms (i.e., Condition a to d) was 38.1 (13.2). More 
women participated: 68.5% of the sample were female, 31.3% were male, and 0.2% other. The popular 
preventive actions were covering mouth and nose (with masks, handkerchiefs, etc.) when coughing 
or sneezing (90.4%), washing hands with soap (89.8%), and hand disinfection with alcohol (66.4%) in 
the group without symptoms. Table 2 shows the proportion of participants with each preventive 
action stratified by symptomatic conditions on two or three time points in each prefecture, when the 
banners were presented and massive flow of participation was observed, showing that the preventive 
actions have not largely changed during the study period. 
  
The timeline of the proportion of each condition for each day from February 1 to March 30, 2020, is 
shown in Figure 1 and Figure 2. Figure 1 depicts the proportions and the number of confirmed cases 
in the three prefectures. The significant change points were observed on March 24, 2020 for Condition 
a (p=0.036), and March 23, 2020 for Condition b, c and d (p=0.012, <0.001 and 0.024, respectively). 
Figure 2 indicates the proportions for each prefecture, also showing that the significant change-points 
were March 24, 2020 for Condition a (p<0.001) and March 23, 2020 for Condition b, c and d (p<0.001, 
respectively) in Kanagawa Prefecture; March 7, 2020 for Condition b (p<0.001) and March 8, 2020 for 
Condition d (p<0.001) in Aichi Prefecture; and March 14, 2020 for Condition b and d (p<0.001, 
respectively), March 15, 2020 for Condition c (p=0.039) in Shiga Prefecture.  
  
The proportion of participants with each non-specific symptom among participants with comorbidities 
and pregnant are shown in Figure 3. The participants with chronic obstructive pulmonary disease, 
immunosuppressant treatment, or malignant tumor with anticancer drugs have fever more than those 
with the other comorbidities and pregnancy.  
 
Last, we validated whether COOPERA captures the COVID-19 situation by comparing the proportions 
in Kanagawa Prefecture with the confirmed cases of COVID-19 (Figure 4). We found significant 
correlation between T1 and T2 with 0 to 3 days delay, suggesting that non-specific symptoms reported 
in COOPERA captures the COVID-19 epidemic in the region and is a powerful tool to infer the trend of 
COVID-19 pandemic. Similar results were obtained in a sensitivity analysis where the study period was 
divided into two periods before and after the start date. In addition, the CCF between the proportion 
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of the participants with fever and the reported number of influenza cases in Kanagawa Prefecture was 
calculated (Supplementary Figure 2), showing no significant positive correlation between them (with 
p = 0.56 - 0.99 for each lag between -5 to 5 days).  
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Discussion 
In this study, we used the novel health care support system, COOPERA, and analyzed over 200,000 
observations in three prefectures in Japan. We found that 96.93% of participants had no symptom 
and the proportion of participants with fever significantly correlated with the number of COVID-19-
positive cases after 0 to 3 days, suggesting that a questionnaire-based massive epidemiological 
monitoring may be able to capture the actual epidemic situation. This result was robust even when 
we divided the study period into two periods before and after the start date. However, the number 
of participants with fever includes both COVID-19 cases and other cases with fever due to common 
cold or influenza. Thus, it is possible that the proportions we have shown here do not directly 
represent COVID-19 prevalence. To address this, we calculated the CCF between the proportion and 
the reported number of influenza cases and obtained no significant positive correlation between them 
(Supplementary figure 2). This suggests the system has (at least partially) captured the COVID-19 
epidemiological situation.  
 
Like other infectious diseases including SARS-CoV and MERS-CoV, SARS-CoV-2 is also a coronavirus 
capable of human-to-human transmission, and those who have comorbidities are at high risk of 
mortality [19-21]. Our results imply that those who have chronic comorbidities, especially COPD, 
immunosuppressant treatment, or malignant tumor, might be more susceptible to COVID-19 infection. 
Further, in terms of preventive action, cough etiquette and handwashing with soap were common 
preventive actions (around 90%) while less than 10% of the participants executed telework and 
stagger commuting hours during the study period. This result might indicate that most people are 
already implementing individual-level preventive actions such as handwashing, while society-level 
preventive efforts, which require governmental or community support, are still not being properly 
implemented and need to be more strongly encouraged. Given that teleworking in particular is not an 
individual choice and is a v ry important non-pharmaceutical intervention, the governments of these 
prefectures need to consider further measures to ensure companies make teleworking available to 
their staff on a wider basis. 
 
The characteristics of COOPERA can be contrasted with existing infectious disease surveillance [22, 
23]. For example, there is a survey in Japan that collects information on pharmacy dispensing with the 
aim of early detection of domestic outbreaks of influenza. In addition, there is a survey on the 
implementation of school closure due to outbreaks of influenza in order to capture the epidemic. On 
the other hand, COOPERA is characterized by the ability to detect signs of an epidemic before it occurs 
in an area. With COOPERA, LINE users can immediately register their symptoms via LINE. In other 
words, it has a high degree of immediacy in that it can collect data before visits to pharmacies, school 
closures, and other measures are taken. In addition, COOPERA can also track the change over time of 
a user's individual symptoms (e.g. when they appeared and how many days until they recovered). 
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Because personal protective equipment is in short supply and there is a risk of infection among 
healthcare professionals, it is not realistic to increase the number of PCR tests immediately. The fact 
that there is a correlation between the number of PCR-positive cases and the proportion of symptoms 
detected by COOPERA in this study suggests that COOPERA may be able to detect the scale of the 
spread of infection and the location of the outbreak when the number of infected cases increases and 
it becomes even more difficult to grasp the actual situation by PCR. 
 
This study has several limitations. The first one is bias of participants. Since COOPERA monitoring was 
based on the online platform LINE and used a non-random sampling scheme, our findings might be 
influenced by selection bias: those who have no access to the internet or smartphone may be 
underrepresented. In addition, there is a possibility that LINE users who have a relatively high level of 
health awareness or are worried about some symptoms tend to respond to the system. Therefore the 
proportion of participants with symptoms might have overestimated the prevalence of people with 
symptoms. In addition, it should be noted that the results showed a low percentage of positive 
symptoms in the day when the banner was displayed. There is a possibility that the participants who 
answered the questions on the day the banner was displayed were not suffered by disease conditions 
preventing them from joining the system at the moment, consequently underestimating the actual 
proportion of people with the symptoms. Conversely, the participants who answered the questions 
before or after the period of banner display could be more motivated to participate in the system if 
any symptoms present, which might end up with overestimating the percentage of symptomatic 
participants. Unfortunately, we only have information on the population of LINE users, which is 
claimed by the company to be about 83 million in total, and there is no detailed distribution data 
regarding the participants’ background such as sex, age, or prefecture. Therefore, it is difficult to verify 
selection bias because it is not possible to evaluate the response rate among users and compare the 
demographic characteristics of non-respondents and respondents. In addition, since the detailed and 
analyzable data on those who received PCR testing was not publicly available, it should be noted that 
the CCF result might include this bias, which is difficult to examine. 
 
Second, it should be noted that the system could not avoid recall bias. In this study, COOPERA 
monitoring included questions regarding symptoms in the last month. People may not remember the 
symptoms in the last month accurately. This recall bias may have created upward trend of the 
proportion with symptoms toward the start of the system.  
 
Third, given the selection bias and recall bias in COOPERA, Figure 1 may give an exaggerated 
impression that the trend of the number of COVID-19 has been dramatically changed during the study 
period. In the figure, we showed the proportion of participants who have symptoms reflecting past 
symptomatic experience. However, trends in the daily proportion using only the "current symptom at 
each study period" data are shown in Supplementary Figure 3. No exponential trends were found, 
suggesting that the results of this study may overestimate the true prevalence of symptoms. However, 
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if only "current symptoms" are used, the number of respondents varies greatly from day to day, and 
the calculation of the percentage is not stable, as can be observed in the Supplementary Figure 3. For 
example, in Kanagawa Prefecture, there are several peaks, but the timing of the peak at the bottom 
coincides with the timing of the COOPERA information released at the Kanagawa Governor's press 
conference. This peak may have occurred as a result of the increase in the number of respondents 
following the press conference and media coverage of COOPERA, with the percentage stabilizing only 
for that day. By taking into account the "symptoms of the past month", the percentage calculation is 
stabilized as the information of the respondents on a given day is used to calculate the percentage 
over the past month (with a recall bias, of course).  
 
Conclusions 
In summary, this study is the first report based on a large-scale (over 200,000 participants) health care 
support system in Japan. Significant correlation between the time trend of participants with symptom 
with the time trend of PCR-confirmed cases supports the utility of the system in monitoring the COVID-
19 epidemiological situation in Japan.   
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Figure legends 
Figure 1: Trend in the proportion of non-specific symptoms in three prefectures. Red line, green line, 
blue line, and purple line indicate the proportion of participants who have a fever (a), a strong feeling 
of weariness or shortness of breath (b), both (a) and (b), and either (a) or (b), respectively. Gray bars 
indicate the reported number of COVID-19-positive cases in three prefectures.  
 
Figure 2: One month trend in each prefecture (left: Kanagawa, middle: Aichi, right: Shiga). Red line, 
green line, blue line, and purple line indicate the proportion of participants who have a fever (a), a 
strong feeling of weariness or shortness of breath (b), both (a) and (b), and either (a) or (b), 
respectively. Gray bar indicates the reported number of COVID-19-positive cases in each prefecture. 
Pink bands are the banner periods. 
 
Figure 3: The proportion of participants with each non-specific symptom among participants with 
comorbidities and pregnant. 1. Malignant tumor with anticancer drugs, 2. Malignant tumor without 
anticancer drugs, 3. Cardiovascular diseases, 4. Kidney diseases, 5. Diabetes mellitus, 6. In dialysis 
treatment, 7. Chronic obstructive pulmonary disease, 8. Treatment with immunosuppressant, 9. 
Pregnant.  
 
Figure 4: Cross correlation function between the time series of reported number of COVID-19 cases 
and the shifted time series of the proportion of non-specific symptoms (shifted days between -10 to 
10). ** p<0.01, * p<0.05 
 
Supplementary Materials 
Supplementary Table 1: Demographic characteristics of the participants by health states during the 
study period for Kanagawa, Aichi and Shiga, as of March 30, 2020 (n (% in column, % in row)). SD: 
standard deviation. * For the purpose of anonymization, all cells with less than five people are 
indicated as NA. In addition, when the number of persons of cells less than five can be uniquely 
calculated by a combination of numbers (n, %) of a plurality of cells, all the cells of the combination 
are set to NA (cells with fewer samples are labeled NA preferentially). 
 
Supplementary Figure 1: Map of selected three prefectures in Japan. 
 
Supplementary Figure 2: Weekly trend in the proportion of participants who have a fever (left) and 
the reported number of influenza cases (middle) and cross correlation function between them (right). 
Blue line in right panel is standard deviation. ACF is autocorrelation function.  
 
Supplementary Figure 3: Trend in the proportion of new participants who have non-specific symptoms 
in each prefecture (left: Kanagawa, middle: Aichi, right: Shiga). Red line, green line, blue line, and 
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purple line indicate the proportion of participants who have a fever (a), a strong feeling of weariness 
or shortness of breath (b), both (a) and (b), and either (a) or (b), respectively. 
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Table 1: Demographic characteristics of the participants by health states during the study period for the three prefectures-combined, as of March 30, 2020 
(n (% in column, % in row)) 
Total, n=206218      
 No symptom 
(n=199,891, 96.93%) 
(a) Fever ≥ 37.5℃ (n=2,821, 
1.37%) 
(b) Strong feeling of weariness or 
shortness of breath (n=4,916, 
2.38%) 
Both (a) and (b) 
(n=1,410, 0.68%) 
Either (a) or (b) 
(n=6,327, 3.07%) 
Age, years           
Mean (SD) 44.36 (13.18) 37.67 (14.49) 38.17 (12.62) 37.44 (13.96) 38.11 (13.19) 
Range (Min–Max) 13-101 13-93 13-93 13-93 13-93 
13–19 6956 (3.48, 94.96) 220 (7.80, 3.00) 239 (4.86, 3.26) 90 (6.38, 1.23) 369 (5.83, 5.04) 
20–29 19092 (9.55, 93.48) 642 (22.76, 3.14) 1032 (20.99, 5.05) 343 (24.33, 1.68) 1331 (21.04, 6.52) 
30–39 42844 (21.43, 95.78) 821 (29.10, 1.84) 1485 (30.21, 3.32) 416 (29.50, 0.93) 1890 (29.87, 4.22) 
40–49 61119 (30.58, 97.49) 605 (21.45, 0.97) 1279 (26.02, 2.04) 311 (22.06, 0.50) 1573 (24.86, 2.51) 
50–59 45246 (22.64, 98.29) 298 (10.56, 0.65) 632 (12.86, 1.37) 145 (10.28, 0.32) 785 (12.41, 1.71) 
60–69 18355 (9.18, 98.80) 120 (4.25, 0.65) 152 (3.09, 0.82) 50 (3.55, 0.27) 222 (3.51, 1.20) 
70–79 5654 (2.83, 97.85) 96 (3.40, 1.66) 77 (1.57, 1.33) 49 (3.48, 0.85) 124 (1.96, 2.15) 
80–89 604 (0.30, 95.12) NA NA NA NA 
≥90 21 (0.01, 91.30) NA NA NA NA 
Sex      
Female 137286 (68.68, 97.18) 1648 (58.42, 1.17) 3117 (63.41, 2.21) 788 (55.89, 0.56) 3977 (62.86, 2.82) 
Male 62297 (31.17, 96.41) NA 1776 (36.13, 2.75) NA 2323 (36.72, 3.59) 
Other 308 (0.15, 91.94) NA 23 (0.47, 6.87) NA 27 (0.43, 8.06) 
Pregnant 2644 (1.32, 96.81) 27 (0.96, 0.99) 78 (1.59, 2.86) 18 (1.28, 0.66) 87 (1.38, 3.19) 
Occupation      
Self-employed 15329 (7.67, 97.16) 205 (7.27, 1.30) 355 (7.22, 2.25) 112 (7.94, 0.71) 448 (7.08, 2.84) 
Employees 76616 (38.33, 96.55) 1213 (43.00, 1.53) 2132 (43.37, 2.69) 610 (43.26, 0.77) 2735 (43.23, 3.45) 
Public officials 10227 (5.12, 96.92) 157 (5.57, 1.49) 259 (5.27, 2.45) 91 (6.45, 0.86) 325 (5.14, 3.08) 
Student 10633 (5.32, 95.00) 309 (10.95, 2.76) 381 (7.75, 3.40) 130 (9.22, 1.16) 560 (8.85, 5.00) 
Acce
pted 
Versi
on
 19 
Part–time workers 39235 (19.63, 97.85) 345 (12.23, 0.86) 680 (13.83, 1.70) 163 (11.56, 0.41) 862 (13.62, 2.15) 
Unemployed 33286 (16.65, 97.37) 374 (13.26, 1.09) 704 (14.32, 2.06) 179 (12.70, 0.52) 899 (14.21, 2.63) 
Others 14565 (7.29, 96.69) 218 (7.73, 1.45) 405 (8.24, 2.69) 125 (8.87, 0.83) 498 (7.87, 3.31) 
Taking antifebrile medications (Loxonin, Caronal, etc.)      
Current 4852 (2.43, 77.53) 847 (30.02, 13.53) 1033 (21.01, 16.51) 474 (33.62, 7.57) 1406 (22.22, 22.47) 
Past one month 11213 (5.61, 92.74) 323 (11.45, 2.67) 743 (15.11, 6.15) 188 (13.33, 1.55) 878 (13.88, 7.26) 
Diseases currently undergoing treatment (multiple 
answers) 
     
Malignant tumor with anticancer drugs 1100 (0.55, 95.16) 33 (1.17, 2.85) 43 (0.87, 3.72) 20 (1.42, 1.73) 56 (0.89, 4.84) 
Malignant tumor without anticancer drugs 2197 (1.10, 97.26) 26 (0.92, 1.15) 49 (1.00, 2.17) 13 (0.92, 0.58) 62 (0.98, 2.74) 
Cardiovascular diseases 4112 (2.06, 95.92) 67 (2.38, 1.56) 150 (3.05, 3.50) 42 (2.98, 0.98) 175 (2.77, 4.08) 
Kidney diseases 1553 (0.78, 94.29) 37 (1.31, 2.25) 85 (1.73, 5.16) 28 (1.99, 1.70) 94 (1.49, 5.71) 
Diabetes mellitus 7152 (3.58, 96.25) 141 (5.00, 1.90) 222 (4.52, 2.99) 84 (5.96, 1.13) 279 (4.41, 3.75) 
In dialysis treatment 202 (0.10, 95.28) 6 (0.21, 2.83) 10 (0.20, 4.72) 6 (0.43, 2.83) 10 (0.16, 4.72) 
Chronic obstructive pulmonary disease 580 (0.29, 92.06) 18 (0.64, 2.86) 46 (0.94, 7.30) 14 (0.99, 2.22) 50 (0.79, 7.94) 
Treatment with immunosuppressant 2191 (1.10, 95.26) 52 (1.84, 2.26) 85 (1.73, 3.70) 28 (1.99, 1.22) 109 (1.72, 4.74) 
Preventive  measures (multiple answers)      
Washing hands in running water 115017 (57.54, 96.88) 1601 (56.75, 1.35) 2882 (58.62, 2.43) 779 (55.25, 0.66) 3704 (58.54, 3.12) 
Washing hands with soap and water 179379 (89.74, 97.11) 2344 (83.09, 1.27) 4146 (84.34, 2.24) 1153 (81.77, 0.62) 5337 (84.35, 2.89) 
Hand disinfection with alcohol 132812 (66.44, 97.20) 1656 (58.70, 1.21) 2969 (60.39, 2.17) 793 (56.24, 0.58) 3832 (60.57, 2.80) 
Etiquette (masks, handkerchiefs, etc.) in case of 
coughing or sneezing 
180638 (90.37, 97.06) 2378 (84.30, 1.28) 4265 (86.76, 2.29) 1169 (82.91, 0.63) 5474 (86.52, 2.94) 
        Take time off from school or work when you have     
        a fever or other symptoms 
87909 (43.98, 96.84) 1480 (52.46, 1.63) 2106 (42.84, 2.32) 715 (50.71, 0.79) 2871 (45.38, 3.16) 
Gargling with water 114613 (57.34, 97.25) 1406 (49.84, 1.19) 2489 (50.63, 2.11) 651 (46.17, 0.55) 3244 (51.27, 2.75) 
Gargling with Isozine 28792 (14.40, 96.97) 364 (12.90, 1.23) 709 (14.42, 2.39) 174 (12.34, 0.59) 899 (14.21, 3.03) 
Regular ventilation 99838 (49.95, 97.48) 1102 (39.06, 1.08) 2033 (41.35, 1.98) 549 (38.94, 0.54) 2586 (40.87, 2.52) 
Maintaining humidity 61086 (30.56, 97.60) 647 (22.94, 1.03) 1164 (23.68, 1.86) 310 (21.99, 0.50) 1501 (23.72, 2.40) 
A well–balanced diet 99222 (49.64, 97.98) 873 (30.95, 0.86) 1569 (31.92, 1.55) 396 (28.09, 0.39) 2046 (32.34, 2.02) 
Regular exercise 52757 (26.39, 98.26) 420 (14.89, 0.78) 704 (14.32, 1.31) 188 (13.33, 0.35) 936 (14.79, 1.74) 
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Getting plenty of rest 101439 (50.75, 97.81) 994 (35.24, 0.96) 1750 (35.60, 1.69) 471 (33.40, 0.45) 2273 (35.93, 2.19) 
Telework 14572 (7.29, 96.98) 169 (5.99, 1.12) 382 (7.77, 2.54) 97 (6.88, 0.65) 454 (7.18, 3.02) 
Staggered commuting 19046 (9.53, 96.85) 244 (8.65, 1.24) 496 (10.09, 2.52) 121 (8.58, 0.62) 619 (9.78, 3.15) 
Avoidance of crowds other than staggered 
commuting 
49466 (24.75, 97.76) 431 (15.28, 0.85) 893 (18.17, 1.76) 193 (13.69, 0.38) 1131 (17.88, 2.24) 
Staying up-to-date on COVID-19 119088 (59.58, 97.46) 1216 (43.11, 1.00) 2451 (49.86, 2.01) 566 (40.14, 0.46) 3101 (49.01, 2.54) 
Other preventive measures 3000 (1.50, 97.09) 22 (0.78, 0.71) 83 (1.69, 2.69) 15 (1.06, 0.49) 90 (1.42, 2.91) 
No preventive measures 716 (0.36, 90.40) 42 (1.49, 5.30) 64 (1.30, 8.08) 30 (2.13, 3.79) 76 (1.20, 9.60) 
      
SD: standard deviation. * For the purpose of anonymization, all cells with less than five people are indicated as NA. In addition, when the number of persons 
of cells less than five can be uniquely calculated by a combination of numbers (n, %) of a plurality of cells, all the cells of the combination are set to NA (cells 
with fewer samples are labeled NA preferentially).
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Table 2: Trends in proportions of preventive measures taken for Kanagawa, Aichi, and Shiga 
prefectures 
Kanagawa 
Mar 6 
(n=23944) 
Mar 12 
(n=8033) 
Mar 27 
(n=23625) 
Washing hands in running water 57.73 56.67 55.38 
Washing hands with soap and water 91.10 90.64 91.89 
Hand disinfection with alcohol 66.28 66.36 66.23 
Etiquette (masks, handkerchiefs, etc.) in case of coughing or sneezing 91.68 91.39 91.18 
Take time off from school or work when you have a fever or other 
symptoms 45.29 46.62 45.17 
Gargling with water 60.67 58.42 59.64 
Gargling with Isozine 16.13 15.75 14.85 
Regular ventilation 48.52 48.56 54.12 
Maintaining humidity 35.14 33.52 30.30 
A well–balanced diet 51.77 51.33 52.16 
Regular exercise 26.47 26.99 28.11 
Getting plenty of rest 53.22 50.64 51.92 
Telework 7.08 9.32 9.36 
Staggered commuting 11.00 12.88 11.39 
Avoidance of crowds other than staggered commuting 27.38 28.22 25.60 
Staying up-to-date on COVID-19 59.48 61.89 61.50 
Other preventive measures 1.85 1.53 1.64 
No preventive measures 0.36 0.22 0.36 
    
Aichi  
Mar 19 
(n=22361) 
Mar 27 
(n=16083) 
Washing hands in running water  59.13 59.39 
Washing hands with soap and water  85.90 86.28 
Hand disinfection with alcohol  65.05 64.53 
Etiquette (masks, handkerchiefs, etc.) in case of coughing or sneezing  89.09 88.67 
Take time off from school or work when you have a fever or other 
symptoms 
 
40.92 40.75 
Gargling with water  52.49 54.26 
Gargling with Isozine  13.59 12.34 
Regular ventilation  47.98 47.21 
Maintaining humidity  28.06 27.51 
A well–balanced diet  45.82 46.62 
Regular exercise  25.39 25.06 
Getting plenty of rest  48.09 50.07 
Telework  3.83 4.28 
Staggered commuting  5.64 5.88 
Avoidance of crowds other than staggered commuting  21.87 21.78 
Staying up-to-date on COVID-19  54.54 58.15 
Other preventive measures  1.40 1.66 
No preventive measures  0.51 0.52 
    
Shiga  
Mar 19 
(n=6522) 
Mar 27 
(n=3283) 
Washing hands in running water  55.52 55.47 
Washing hands with soap and water  86.55 86.45 
Hand disinfection with alcohol  64.21 62.93 
Etiquette (masks, handkerchiefs, etc.) in case of coughing or sneezing  87.47 88.33 
Take time off from school or work when you have a fever or other 
symptoms 
 
40.34 38.99 
Gargling with water  51.30 51.51 
Gargling with Isozine  13.43 12.00 
Regular ventilation  43.65 43.74 
Maintaining humidity  26.76 23.73 
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A well–balanced diet  45.31 47.58 
Regular exercise  25.50 25.65 
Getting plenty of rest  46.20 48.04 
Telework  2.70 2.95 
Staggered commuting  3.74 3.75 
Avoidance of crowds other than staggered commuting  19.23 18.58 
Staying up-to-date on COVID-19  55.57 57.08 
Other preventive measures  1.26 1.22 
No preventive measures  0.51 0.61 
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